Aug 28, 2016

Stem-Cell Therapy Trials Miss Mark but Keep Hope Alive

Two stem-cell trials, two negative primary end points, but signals of benefit in each may keep hope alive in patients with heart failure (HF), despite a decade of disappointment in the field.
A phase 2a trial found that IV administration of allogeneic ischemia-tolerant mesenchymal stem cells (itMSC) derived from a single healthy donor did not effect left ventricular (LV) function in 22 patients with nonischemic HF and an ejection fraction <40% (P=0.99). READ FULL ARTICLE